Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
azathioprine, Quantity: 50 mg
Sandoz Pty Ltd
Tablet, film coated
Excipient Ingredients: magnesium stearate; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; maize starch; purified talc; povidone; hypromellose; microcrystalline cellulose; PEG-8 stearate
Oral
100 tablets
(S4) Prescription Only Medicine
Immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with higher dosage and prolonged usage of corticosteroids. Azathioprine, in combination with cortocosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. Azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.
Visual Identification: Round, biconvex white to yellowish white film-coated tablets, with one-sided breaking notch.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2014-07-23
Product and Consumer Medicine Information Licence ------------------------- ACCESS TERMS FOR PRODUCT INFORMATION AND CONSUMER MEDICINE INFORMATION DOCUMENTS ("LICENCE") PARTIES YOU or YOUR means any legal person or entity who accesses or downloads a PI Document or CMI Document from Our website and US, WE or OUR means the COMMONWEALTH OF AUSTRALIA as represented by the THERAPEUTIC GOODS ADMINISTRATION ABN 40 939 406 804 of 136 Narrabundah Lane, Symonston ACT 2609, Australia. OPERATIVE PROVISIONS * NATURE OF AGREEMENT * 1.1 This Licence specifies the terms and conditions of Your access and use of PI Documents and CMI Documents made available to the general public by Us via Our website. * 1.2 You acknowledge and agree that accessing PI Documents or CMI Documents in accordance with this Licence is beneficial to You because it provides You with product information about therapeutic goods and is beneficial to Us because it assists Us in our portfolio responsibilities. * TERMS OF ACCESS * 2.1 We grant to You a perpetual, non-exclusive, royalty-free, world-wide, irrevocable and non-transferable licence to download, store in cache, display, print and copy a single copy or part of a single copy of a PI Document or CMI Document made available via Our website. * 2.2 If You wish to use any PI Document or CMI Document for purposes other than those specified in clause 2.1 of this Licence, You must seek the permission of the Sponsor. * 2.3 We may remove a PI Document or CMI Document from Our website at any time in Our sole discretion. * EXCLUSION OF LIABILITY * 3.1 You acknowledge and agree that You are responsible for making Your own enquiries to determine whether any PI Document or CMI Document is accurate, up to date and fit for Your purposes. * 3.2 The PI Document or CMI Document is provided to You for the purpose of disseminating health information free of charge for the benefit of the public. This Licence and any PI Document or CMI Document made available to You via Our website is not a substitute fo Διαβάστε το πλήρες έγγραφο
Product and Consumer Medicine Information Licence ------------------------- ACCESS TERMS FOR PRODUCT INFORMATION AND CONSUMER MEDICINE INFORMATION DOCUMENTS ("LICENCE") PARTIES YOU or YOUR means any legal person or entity who accesses or downloads a PI Document or CMI Document from Our website and US, WE or OUR means the COMMONWEALTH OF AUSTRALIA as represented by the THERAPEUTIC GOODS ADMINISTRATION ABN 40 939 406 804 of 136 Narrabundah Lane, Symonston ACT 2609, Australia. OPERATIVE PROVISIONS * NATURE OF AGREEMENT * 1.1 This Licence specifies the terms and conditions of Your access and use of PI Documents and CMI Documents made available to the general public by Us via Our website. * 1.2 You acknowledge and agree that accessing PI Documents or CMI Documents in accordance with this Licence is beneficial to You because it provides You with product information about therapeutic goods and is beneficial to Us because it assists Us in our portfolio responsibilities. * TERMS OF ACCESS * 2.1 We grant to You a perpetual, non-exclusive, royalty-free, world-wide, irrevocable and non-transferable licence to download, store in cache, display, print and copy a single copy or part of a single copy of a PI Document or CMI Document made available via Our website. * 2.2 If You wish to use any PI Document or CMI Document for purposes other than those specified in clause 2.1 of this Licence, You must seek the permission of the Sponsor. * 2.3 We may remove a PI Document or CMI Document from Our website at any time in Our sole discretion. * EXCLUSION OF LIABILITY * 3.1 You acknowledge and agree that You are responsible for making Your own enquiries to determine whether any PI Document or CMI Document is accurate, up to date and fit for Your purposes. * 3.2 The PI Document or CMI Document is provided to You for the purpose of disseminating health information free of charge for the benefit of the public. This Licence and any PI Document or CMI Document made available to You via Our website is not a substitute fo Διαβάστε το πλήρες έγγραφο